

# Metabolites of the Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Smokers' Urine<sup>1</sup>

Steven G. Carmella, Shobha Akerkar, and Stephen S. Hecht

Division of Chemical Carcinogenesis, American Health Foundation, Valhalla, New York 10595

## Abstract

Metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent pulmonary carcinogen, have been quantified in the urine of 11 smokers. They were not detected in nonsmokers' urine. The metabolites, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its glucuronide, were detected in quantities of 0.23–1.0 and 0.57–6.5  $\mu\text{g}/24$  h, respectively. The results of this study provide the first evidence for metabolites of tobacco-specific nitrosamines in human urine.

## Introduction

It has been estimated that up to 90% of lung cancer deaths in the United States are attributable to cigarette smoking (1). The tobacco-specific nitrosamine NNK<sup>2</sup> (Fig. 1) is believed to play an important role in the induction of lung cancer in smokers because it is a potent pulmonary carcinogen in rats, mice, and hamsters inducing tumors at total doses similar to the estimated doses to which smokers are exposed (2, 3). NNK may also be involved in oral and pancreatic cancer associated with the use of tobacco products (3, 4). Although the metabolism of NNK has been extensively studied in laboratory animals, relatively little is known about its uptake and metabolism in humans. We believe that such information is critical to an understanding of mechanisms of cancer induction in humans.

In rodents and monkeys, identified pathways of NNK metabolism include  $\alpha$ -hydroxylation, pyridine-*N*-oxidation, carbonyl reduction to NNAL, and conjugation of NNAL to the diastereomeric glucuronides NNAL-Gluc(I) and NNAL-Gluc(II) (Fig. 1) (2, 5, 6). Previous studies using cultured human tissues or microsomes have shown that NNK is metabolized by  $\alpha$ -hydroxylation and carbonyl reduction (7, 8). Hemoglobin and DNA adducts resulting from  $\alpha$ -hydroxylation of NNK, NNAL, or the related carcinogen NNN have been detected in the blood of smokers or snuff-dippers (9, 10). In this article, we present the first evidence for the presence in smokers' urine of NNK metabolites: NNAL; NNAL-Gluc(I); and NNAL-Gluc(II). Quantitation of NNK metabolites in human urine should greatly facilitate our understanding of its role in tobacco-related cancers.

## Materials and Methods

**Chemicals.** [5-<sup>3</sup>H]NNAL was obtained by NaBH<sub>4</sub> reduction of [5-<sup>3</sup>H]NNK (Chemsyn Science Laboratories, Lenexa, KS). [5-<sup>3</sup>H]NNAL-Gluc(II) was isolated from the urine of a patas monkey treated with [5-<sup>3</sup>H]NNK (6). NNAL,

iso-NNAL, nitrosoguvacoline, and 4-(methylamino)-4-(3-pyridyl)-1-butanone were synthesized (11–13). Bis-trimethylsilyltrifluoroacetamide/1% trimethylchlorosilane was obtained from Regis Chemical Co. (Morton Grove IL).  $\beta$ -Glucuronidase, type IXA, sulfatase, type VIII, and saccharic acid 1,4-lactone were obtained from Sigma Chemical Co. (St. Louis, MO). 3-Acetylpyridine and 2-pyridylcarbinol were obtained from Aldrich Chemical Co. (Milwaukee, WI). The latter was converted to its acetate by treatment with acetic anhydride and triethylamine in CH<sub>2</sub>Cl<sub>2</sub>.

**Apparatus.** HPLC was performed using a Millipore, Waters Division system as previously described (9) and a 3.9-  $\times$  300-mm Bondclone 10 C18 column (Phenomenex, Torrance, CA) with UV detection at 254 nm. Solvent A was H<sub>2</sub>O and solvent B was methanol. The solvent program was 15% B in A for 10 min, then to 45% B in A over 30 min, then back to initial conditions in 5 min, and then held for 25 min prior to the next injection.

GC-TEA was performed with a Model 5890 gas chromatograph (Hewlett-Packard, Palo Alto, CA) interfaced with a Model 610 Thermal Energy Analyzer (Thermedics Inco, Woburn, MA) and a Model D-2000 integrator (Hitachi Instruments, Danbury CT) (14). The gas chromatograph was equipped with a 2-mm  $\times$  12-ft glass column filled with 3% XE-60 on GasChrom Q, 100/200 mesh (Alltech/Applied Sciences, Deerfield, IL). The oven was temperature-programmed as follows: 150°C for 3 min; then 6°C/min to 220°C; and then held for 15 min. The injection port temperature was 230°C and the flow rate was 33 ml/min argon.

GC-MS-SIM was carried out with a Hewlett-Packard Model 5988A instrument, operated in the positive chemical ionization mode with a methane pressure of 0.88 torr, an ionizing energy of 107 eV, and a source temperature of 200°C. For electron impact experiments, the ionizing energy was 70 eV and the source temperature was 200°C. The analyses were performed by splitless injection on a 0.25-mm  $\times$  30-m Econocap SE 54 column (film thickness, 0.25  $\mu\text{m}$ ; Alltech/Applied Sciences), with a 0.32-mm  $\times$  1-m retention gap. The carrier gas was He (head pressure, 12 psi) and the oven temperature was programmed as follows: 100°C for 1 min; then 8°C/min to 180°C; and then held for 30 min.

**Volunteers.** Eleven smokers and 7 nonsmokers ranging in age from 20 to 65 years were recruited. The protocol for collection of urine was approved by the American Health Foundation Institutional Review Board for protection of human subjects.

**Analysis of Urine by GC-TEA.** Twenty-four-h urine samples were collected in 3 liter amber specimen containers (Baxter Scientific Products Division, McGaw Park, IL) to which 10 ml of a solution of 20% ammonium sulfamate (Sigma) in 3.6 *N* H<sub>2</sub>SO<sub>4</sub> had been added to inhibit artifactual nitrosation. Samples were stored at room temperature during collection. Aliquots of 100 ml were adjusted to pH 7 with 10 *N* NaOH. To this was added 0.5 ml of an aqueous solution of [5-<sup>3</sup>H]NNAL-Gluc(II) (2.1 Ci/mmol; 21,000 dpm) as internal standard. The resulting solution was extracted 3 times with equal volumes of ethyl acetate. The aqueous portion (A-1) was saved. A solution of [5-<sup>3</sup>H]NNAL (2.1 Ci/mmol; 100,000 dpm) in 50  $\mu\text{l}$  of methanol was added to the combined ethyl acetate extracts, as internal standard for unconjugated NNAL. The ethyl acetate layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness by rotary evaporation. The residue (Fig. 2, Fraction 1) was dissolved in two 0.5-ml aliquots of H<sub>2</sub>O, which were combined and set aside for subsequent HPLC purification and analysis for NNAL. Twenty  $\mu\text{l}$  of "antifoam B emulsion" (Sigma) were added to the aqueous portion, A-1, which was then concentrated by rotary evaporation (water bath temperature, 35°C) to approximately 70% of its initial volume. The purpose of this step was removal of most of the ethyl acetate, traces of which inhibited  $\beta$ -glucuronidase activity.  $\beta$ -Glu-

Received 11/17/92; accepted 12/31/92.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This study was supported by Grant CA-29580 from the National Cancer Institute.

<sup>2</sup> The abbreviations used are: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNAL-Gluc(I) and NNAL-Gluc(II), two diastereomers of [4-(methylnitrosamino)-1-(3-pyridyl)but-1-yl]- $\beta$ -*O*-*D*-glucosiduronic acid; NNAL-TMS, trimethylsilyl ether of NNAL; iso-NNAL, 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanol; HPLC, high performance liquid chromatography; GC-TEA, combined gas chromatography-thermal energy analyzer; GC-MS-SIM, combined gas chromatography-mass spectrometry-selected ion monitoring.




Fig. 1. Structures of the compounds.




Fig. 2. Analytical scheme for quantitation of NNAL and NNAL-Gluc in smokers' urine.

curonidase, 5000 units, was added and the sample was incubated at 37°C for 16 h with gentle shaking. After the incubation was complete, the pH was adjusted to 2 with concentrated HCl and the resulting solution was extracted 2 times with ethyl acetate. The pH of the aqueous layer was then adjusted to 7 with concentrated NaOH, and the solution was extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and the CH<sub>2</sub>Cl<sub>2</sub> was removed by rotary evaporation. The residue (Fig. 2, Fraction 2) was taken up in two 0.5-ml aliquots of H<sub>2</sub>O which were combined for HPLC analysis.

Fractions 1 and 2 were prepared for HPLC analysis. Fifty μg of H<sub>2</sub>O containing 50 μg of 3-acetylpyridine and 50 μg of 2-pyridylcarbinol acetate, which were used as retention time markers (19 and 29 min, respectively), were added to each fraction. The pH of the resulting mixtures was adjusted to 7 and they were injected on HPLC. The region corresponding in retention time to NNAL (approximately 20–27 min) was collected in a 15-ml disposable glass centrifuge tube. The collected material was concentrated to dryness on a Model SVC200H Speedvac concentrator (Savant Instruments, Farmingdale, NY) at approximately 35°C. The residue was transferred to a 100-μl glass-lined mi-

crovial (#225195; Wheaton, Millville, NJ) with three 50-μl portions of methanol. The methanol was removed by Speedvac evaporation.

To the residue was added 5 μl of CH<sub>3</sub>CN containing 30 ng of iso-NNAL and 20 ng of nitrosoguvacoline, which were used as silylation and injection standards, respectively. After thorough mixing, 5 μl of bis-trimethylsilyltrifluoroacetamide containing 1% trimethylchlorosilane were added, the vial was capped, and the mixture was heated at 40°C for 1 h. Then 5 μl were analyzed by GC-TEA. The remaining 50% of the sample was washed into a scintillation vial with CH<sub>3</sub>CN and methanol for determination of recovery of radioactivity.

Amounts of NNAL in the samples were determined by integration of the peak corresponding in retention time to NNAL-TMS (see Fig. 3) and comparison to a standard curve. Efficiency of silylation was generally quantitative, as determined by integration of the peak corresponding in retention time to iso-NNAL-TMS. Results were corrected for recovery of internal and injection standards.

Some urine samples were analyzed for NNK. [5-<sup>3</sup>H]NNAL, 114,000 dpm, was added to the ethyl acetate extract of urine. This was analyzed by HPLC as described above and the regions corresponding in retention time to NNAL and NNK were collected. The NNK fraction was concentrated to remove methanol and treated with 5 mg NaCNBH<sub>3</sub>. Excess reducing agent was quenched with 2 N HCl and the mixture was neutralized and then extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>. This was concentrated, and the residue was silylated and analyzed as above for NNAL-TMS.

**Preparation of Urine for Analysis by GC-MS-SIM.** Morning void (approximately 800 ml) from smokers 2 and 3 (Table 1) was combined. Fraction 2 was obtained essentially as described above, with allowances for the larger scale being made. Reverse-phase HPLC was carried out with a 7.8 × 300-mm Bondclone 10 C18 column using the program described above, with a flow rate of 4 ml/min. The fraction containing NNAL was further purified by normal phase HPLC with a 4.6 × 250-mm Microsorb-MV 5-μm silica column (Rainin Instrument Co., Woburn, MA) with elution by solvents A (50/50:CHCl<sub>3</sub>/hexane) and B (20% isopropyl alcohol in solvent A). The solvent program proceeded from 70 to 50% A in 15 min and was then held for 25 min. The flow rate was 1 ml/min. Eluent was collected from 24 to 45 min, concentrated to dryness, and silylated.

## Results

The analytical method is summarized in Fig. 2. Fraction 1, obtained by extraction with ethyl acetate, contained unconjugated NNAL. The aqueous portion of the urine was treated with β-glucuronidase to release NNAL from NNAL-Gluc(I) and NNAL-Gluc(II). The released NNAL was enriched by partitioning to give Fraction 2. Each fraction was further purified by HPLC prior to silylation and analysis by GC-TEA. Typical GC-TEA traces from analyses of Fraction 2 are illustrated in Fig. 3.

The identity of NNAL in Fraction 2 of smokers' urine was confirmed by GC-MS-SIM. Major peaks in the chemical ionization spectrum of standard NNAL-TMS are *m/z* 282 (*M* + 1; relative intensity,

Table 1 NNAL and NNAL-Gluc in smokers' urine

Subject	Sex	Cigarettes/day	nmol (μg)/24 h		Cotinine (mg/24 h) <sup>a</sup>
			NNAL	NNAL-Gluc	
1	M	36	2.2 (0.46) <sup>b</sup>	11 (4.4) <sup>b</sup>	15.3
2	F	29	1.8 (0.37)	14 (5.5)	20.0
3	F	20	1.7 (0.35)	17 (6.5)	6.82
4 <sup>c</sup>	M	25	2.1 (0.43)	4.4 (1.7)	3.39
5	F	20	3.3 (0.69)	10 (3.9)	7.31
6 <sup>c</sup>	F	29	4.8 (1.0)	10 (3.9)	8.80
7	F	25	1.1 (0.23)	11 (4.2)	8.22
8	F	25	3.3 (0.70)	1.5 (0.57)	2.28
9 <sup>c</sup>	F	12	4.2 (0.87)	3.6 (1.4)	5.92
10 <sup>c</sup>	F	20	1.4 (0.29)	8.6 (3.3)	2.71
11	F	15	1.3 (0.28)	7.2 (2.8)	4.22

<sup>a</sup> Values include some 3'-hydroxycotinine.

<sup>b</sup> Numbers in parentheses, μg.

<sup>c</sup> Levels of NNK in mainstream smoke of the cigarettes used by these volunteers were available. These were multiplied by cigarettes/day to obtain estimated daily dose of NNK, as follows (nmol): 4, 16.4; 6, 22.7; 9, 7.7; 10, 13.0.




Fig. 3. GC-TEA traces of Fraction 2 from a smoker and a nonsmoker. I.S., injection standard nitrosoguvacoline and silylation standard (iso-NNAL).

100), 162(83), and 132(43). As shown in Fig. 4, these peaks were all present at the retention time of NNAL-TMS in the GC-MS-SIM analysis of Fraction 2. The ratios of the MS responses for  $m/z$  282, 162, and 132 were 1:0.67:0.32 in the sample compared to 1:0.83:0.43 in the spectrum of standard NNAL-TMS. Similar results were obtained using the electron impact mode (data not shown).

Some experiments were carried out without  $\beta$ -glucuronidase, or with sulfatase instead of  $\beta$ -glucuronidase, or with  $\beta$ -glucuronidase in




Fig. 4. GC-MS-SIM analysis (chemical ionization mode) of NNAL-TMS from Fraction 2 of a smoker's urine (see text for details).

the presence of saccharic acid 1,4-lactone, an inhibitor of  $\beta$ -glucuronidase activity. No NNAL was detected in Fraction 2 of these samples. In another series of experiments, the aqueous portion of one smoker's urine was injected on HPLC and the eluents corresponding in retention time to NNAL-Gluc(I), NNAL-Gluc(II), and NNAL were collected. The NNAL-Gluc(I) and (II) fractions were treated with  $\beta$ -glucuronidase and the resulting mixtures as well as the NNAL fraction were analyzed by GC-TEA after silylation. NNAL-TMS was detected in all three fractions, which is consistent with the presence of NNAL-Gluc(I) and (II) as well as unconjugated NNAL in smokers' urine.

The possibility that NNAL or NNAL-Gluc could have formed artifactually during analysis of the urine samples was considered although the amine precursors to NNAL and NNAL-Gluc are not known to be constituents of smokers' urine. Urine was collected from a smoker and divided into three 50-ml aliquots, each of which was mixed with ammonium sulfamate/ $H_2SO_4$  as described in "Materials and Methods." The first aliquot was treated with 0.5 mg of 4-(methylamino)-4-(3-pyridyl)-1-butanol, the amine precursor to iso-NNAL, and was allowed to stand for 24 h at room temperature. It was then analyzed for iso-NNAL. The purpose of this experiment was to determine the extent of nitrosation, under our collection and analysis conditions, of a secondary amine that is readily nitrosated and is structurally related to the secondary amine precursor to NNAL, which was not available. The yield of iso-NNAL in this experiment was 0.01%. The second 50-ml aliquot was treated with 4.5 mg  $NaNO_2$ , which is equivalent to the amount of  $NaNO_3$  typically present in 50 ml of urine (15). [Urine samples from noninfected individuals do not normally contain nitrite (15)]. The third aliquot was not treated. These two aliquots were allowed to stand for 24 h at room temperature and were then analyzed. Levels of NNAL in these two aliquots were the same, whereas levels of NNAL-Gluc were about 20% higher in the  $NaNO_2$  treated than in the untreated aliquot. Collectively, these data indicate that artifactual formation of NNAL or NNAL-Gluc under our conditions is minimal.

Recoveries of  $[5-^3H]NNAL$  and  $[5-^3H]NNAL-Gluc(II)$  using the method outlined in Fig. 2 were  $36 \pm 7.7$  and  $30 \pm 5.2\%$ , respectively. Repetitive analyses of one smoker's urine gave values of  $0.66 \pm 0.064$   $\mu g/liter$  NNAL ( $n = 6$ ) and  $2.4 \pm 0.41$   $\mu g/liter$  NNAL-Gluc ( $n = 7$ ). The results of analyses of smokers' urine are summarized in Table 1. One of seven nonsmokers appeared to excrete NNAL-Gluc ( $\sim 0.7$   $\mu g/24$  h); all other nonsmokers' urines were negative.

Six urine samples from smokers were also analyzed for NNK. None was detected.

## Discussion

The data presented here clearly demonstrate that NNAL and NNAL-Gluc are present in smokers' urine. The amounts detected are in the expected range based on the levels of NNK in cigarette mainstream smoke. These data confirm the uptake of NNK by smokers and allow one to estimate its dose. This will be important in further studies evaluating the relationships of NNK to tobacco-induced cancer. The present results do indicate that total uptake of NNK in a lifetime of smoking is comparable to the lowest doses of this carcinogen which induce lung tumors in rodents (4).

It is possible that some of the NNAL and NNAL-Gluc in urine may come from NNAL in cigarette smoke. The presence of NNAL in cigarette smoke has not been reported, although it has been tentatively identified in snuff products, at levels which appear to be considerably lower than those of NNK (16). NNAL has also been detected in the saliva of Sudanese snuff-dippers (17). NNAL, like NNK, is a potent pulmonary carcinogen in the rat and mouse (18–20). It also induces ductal tumors of the pancreas in the rat (20).

The failure to detect NNK was not unexpected based on metabolism studies which have shown that little if any of this nitrosamine is excreted unchanged in laboratory animals (5, 6, 12). The detection of NNAL-Gluc in smokers' urine is consistent with our recent studies of NNK metabolism in the patas monkey, which showed that NNAL-Gluc(I) and (II) were prominent urinary metabolites (6).

Previous studies have shown that hemoglobin adducts, known to result from metabolic activation of NNK, NNAL, and NNN, are elevated in approximately 20% of smokers (9). This presumably relates to higher levels of  $\alpha$ -hydroxylation of these nitrosamines in some smokers. The data in Table 1 indicate that the ratio of NNAL to NNAL-Gluc varies from 0.1 to 2.3. It will be important to determine whether the ratio of free to conjugated NNAL influences levels of hemoglobin and DNA adducts in smokers.

### Acknowledgments

We thank the American Health Foundation Clinical Biochemistry Facility for cotinine analyses and Shantu Amin and his group for synthesizing NNK, iso-NNAL and related standards. We also appreciate the contributions of Shashi S. Kagan and Mirjana Djordjevic.

### References

1. Shopland, D. R., Eyre, H. J., and Pechacek, T. F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? *J. Natl. Cancer Inst.*, **83**: 1142-1148, 1991.
2. Hecht, S. S., and Hoffmann, D. Tobacco-specific nitrosamines: an important group of carcinogens in tobacco and tobacco smoke. *Carcinogenesis (Lond.)*, **9**: 875-884, 1988.
3. Hecht, S. S., and Hoffmann, D. The relevance of tobacco-specific nitrosamines to human cancer. *Cancer Surv.*, **8**: 273-294, 1989.
4. Hecht, S. S., and Hoffmann, D. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine-derived *N*-nitrosamine, and cancer of the lung and pancreas in humans. *In: J. Brugge, T. Curran, E. Harlow, and F. McCormick (eds.), The Origins of Human Cancer: A Comprehensive Review*, pp. 745-755. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1991.
5. Morse, M. A., Eklind, K. I., Toussaint, M., Amin, S. G., and Chung, F.-L. Characterization of a glucuronide metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. *Carcinogenesis (Lond.)*, **11**: 1819-1823, 1990.
6. Hecht, S. S., Trushin, N., Reid-Quinn, C., Burak, E., Jones, A. B., Southers, J., Gombar, C., Carmella, S. G., Anderson, L. M., and Rice, J. M. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites. *Carcinogenesis (Lond.)*, in press, 1993.
7. Castonguay, A., Stoner, G. D., Schut, H. A. J., and Hecht, S. S. Metabolism of tobacco-specific *N*-nitrosamines by cultured human tissues. *Proc. Natl. Acad. Sci. USA*, **80**: 6694-6697, 1983.
8. Smith, T. J., Guo, Z. Y., Gonzalez, F. J., Guengerich, F. P., Stoner, G. D., and Yang, C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. *Cancer Res.*, **52**: 1757-1763, 1992.
9. Carmella, S. G., Kagan, S. S., Kagan, M., Foiles, P. G., Palladino, G., Quart, A. M., Quart, E., and Hecht, S. S. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff-dippers, smokers, and non-smokers. *Cancer Res.*, **50**: 5438-5445, 1990.
10. Foiles, P. G., Akerkar, S. A., Carmella, S. G., Kagan, M., Stoner, G. D., Resau, J. H., and Hecht, S. S. Mass spectrometric analysis of tobacco-specific nitrosamine DNA adducts in smokers and non-smokers. *Chem. Res. Toxicol.*, **4**: 364-368, 1991.
11. Hecht, S. S., Chen, C. B., and Hoffmann, D. Synthesis of *N*-nitrosamino aldehydes. *Tetrahedron Lett.*, **8**: 593-596, 1976.
12. Hecht, S. S., Young, R., and Chen, C. B. Metabolism in the F344 rat of 4-(*N*-methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. *Cancer Res.*, **40**: 4144-4150, 1980.
13. Christensen, S. B., and Krogsgaard-Larsen, P. Preparations of deuterium labelled guvacine and isoguvacine. *J. Labelled Compd.*, **17**: 191-202, 1977.
14. Adams, J. D., Brunnemann, K. D., and Hoffmann, D. Rapid method for the analysis of tobacco-specific *N*-nitrosamines by gas liquid chromatography with a thermal energy analyzer. *J. Chromatogr.*, **256**: 347-351, 1983.
15. Tricker, A. R., Stickler, D. J., Chawla, J. C., and Preussmann, R. Increased urinary nitrosamine excretion in paraplegic patients. *Carcinogenesis (Lond.)*, **12**: 943-946, 1991.
16. Brunnemann, K. D., Genoble, L., and Hoffmann, D. Identification and analysis of a new tobacco-specific *N*-nitrosamine, 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanol. *Carcinogenesis (Lond.)*, **8**: 465-469, 1987.
17. Idris, A. M., Nair, J., Friesen, M., Ohshima, H., Brouet, I., Faustman, E. M., and Bartsch, H. Carcinogenic tobacco-specific nitrosamines are present at unusually high levels in the saliva of oral snuff users in Sudan. *Carcinogenesis (Lond.)*, **13**: 1001-1005, 1992.
18. Castonguay, A., Lin, D., Stoner, G. D., Radok, P., Furuya, K., Hecht, S. S., Schut, H. A. J., and Klaunig, J. E. Comparative carcinogenicity in *A/J* mice and metabolism by cultured mouse peripheral lung of *N*-nitrosanornicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and their analogues. *Cancer Res.*, **43**: 1223-1229, 1983.
19. Hecht, S. S., Jordan, K. G., Choi, C.-I., and Trushin, N. Effects of deuterium substitution on the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in *A/J* mice. *Carcinogenesis (Lond.)*, **11**: 1017-1020, 1990.
20. Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S., and Hecht, S. S. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived *N*-nitrosamines. *Cancer Res.*, **48**: 6912-6917, 1988.



# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Metabolites of the Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Smokers' Urine

Steven G. Carmella, Shobha Akerkar and Stephen S. Hecht

*Cancer Res* 1993;53:721-724.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/53/4/721>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/53/4/721>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.